The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer and better structured cooperation than before. Their common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.

Egis and our consortia partners have won 2,332 billion HUF direct grant in the framework of the innovation tender GINOP-2.2.1-15-2016-00023 for the realization of the above-mentioned project.

Egis Pharmaceuticals PLC acquired Sinuforte from Hartington Business S.L. Under the agreement Egis receives all rights related to the product, a nasal spray indicated for the treatment of sinusitis and other inflammatory diseases of the paranasal sinuses. The company seeks to ensure its growing presence in major export markets through organic growth and targeted acquisitions.

Egis Pharmaceuticals PLC has acquired Sorbifer’s product rights from AstraZeneca. The transaction reinforces Egis’ position on its key markets.

The predecessor of Egis Pharmaceuticals PLC, Dr Wander Pharmaceuticals and Nutriments Ltd. was registered on 19 February 1913.

EGIS-RUS received the honor from Aon Hewitt, the global leader in human resource solutions and its Russian partner AXES Management

Egis Pharmaceuticals has been awarded „Family-friendly workplace”, founded by the Ministry of Human Capacities.

Egis informs about the secondary packaging changes of Suprastin®in tablet forms manufactured by Egis Pharmaceuticals PLC" (Hungary). The secondary packaging receives a new color scheme and visual cues that make the pharmaceutical product more visible in the particular category and more convinient for consumers. At the same time, the composition of the product and its properties remain unchanged.

EGIS-RUS announces the expansion of its Women’s health portfolio by a new brand under Zalain product line. It will be replenished with the new Zalagel® Intim moisturizing gel for intimate hygiene with a unique combination of tea tree oil and weakly alkaline pH 8-9.

EGIS-RUS LLC made rebranding of the popular skin repair products: D-Panthenol Novatenol (cream and ointment) took place D-Panthenol (cream and ointment) on pharmacy shelves.

We inform our customers, partners and consumers about the change packaging design of more than 30 products.

Egis launches in Russia a product with fixed-doses of atorvastatin and ezetimibe in one capsule for the treatment of hypercholesterolemia [1]. Fixed-dose combination (FDC) developed by Egis will increase adherence in patients who take atorvastatin and ezetimibe separately, and a single dose per day should significantly simplify the drug therapy regimen.

Egis has launched to the Russian market a new ezetimibe of European quality that helps to achieve the target level of low-density lipoprotein cholesterol in cases where the statin therapy is not enough. The drug is produced in Hungary (EU) in accordance with Good Manufacturing Practices (GMP). At the same time, the new product is more affordable compared to the original ezetimibe [6], which ensures its high attractiveness for Russian doctors and their patients. The product has already been registered in Russia and sold in Russian pharmacies from October 2021.

Two technology-intensive developments, carried out with state subsidies, were completed at Egis Pharmaceuticals PLC’s Körmend site (Hungary). The investments were inaugurated by Péter Szijjártó, Minister of Foreign Affairs and Trade, and by the company’s CEO, Dr. István Hodász on 15 October.  In addition to a new packaging plant, Egis has also established a plant with special knowledge and technology requirements, typically suitable to manufacture oncology products.  Thus, Egis is now able to implement all value-creating processes within the field of oncology, from development to active ingredient and finished product manufacturing.

Hungarian-based Egis Pharmaceuticals PLC launch in Russia the first fixed drug combination of two lipid-lowering agents: rosuvastatin and ezetimibe.

The project "Egis eco-marathon", aimed at greening the company and its employees, received well-deserved recognition from specialists in the field of event marketing and was among the finalists in the category "Corporate Social Responsibility: Best ESG Project".

EMS (Environmental Management System) of EGIS-RUS successfully passed a certification audit for compliance with ISO 14001:2015 requirements. The audit was conducted by the International Organization for Standardization and Certification Bureau Veritas (Bureau Veritas Certification Rus JSC). Meeting the requirements of the ISO standards confirms the commitment of the management and employees to the highest requirements for climate protection and reduction of their environmental impact.

The project "Improving the living conditions of children in orphanages in Yaroslavl" was recognized as the best in the nomination "Projects to Support Socially Vulnerable Groups of People".

The series of educational webinars “Let's Talk About Women” received the highest award of the “Development of Regions. Best for Russia" in the category “Social Projects and Sustainable Development".

The 11th Russian Pharma Awards ceremony was held on November 24th in Moscow. Based on the results of voting by Russian medical practitioners, Egis' iron-containing product was recognized as the absolute leader in the category "Treatment of anemia in pregnant and lactating women". More than 430 thousand doctors were invited to vote at the communication platform "Doctor at Work".

November 21, 2019: A symposium “New opportunities for reducing cardiovascular risk in the Russian Federation”, organized by EGIS-RUS, was held in the frame of the XIV National Congress of Therapists.

From October 7 to December 22, 2019, there will be a TV broadcasting campaign in support of Sinuforte®. The commercial under the slogan “Do not let sinusitis cling on to you” is broadcasting on the largest federal television channels: Russia, TNT, Muz-TV, Friday, Channel 5, TV-3, Disney, U.